OBJECTIVE: @entity148 are highly prevalent in population of European countries. However, the effect of @entity1092 ( @entity1092 -chrono) on @entity148 ( @entity148 ) has not been studied in a double-blind placebo-controlled design. METHOD: Eighty @entity1 (all @entity1 ) were washout from the all medications. Each @entity1 was randomized to receive either @entity1092 -chrono (40 @entity1 ) for 6 weeks or matched placebo (40 @entity1 ) in a double-blind manner. Eligible @entity1 , in addition to meeting the DSM-IV criteria for @entity148 and having a minimum score of 25 and more on the Hamilton Anxiety Scale, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Hamilton anxiety scale score. Response and side effects with @entity1092 -chrono and placebo were compared by using analysis of variance (ANOVA) and chi-square tests. Six @entity1 did not return for at least one subsequent assessment, leaving 74 @entity1 (36 taking @entity1092 -chrono and 38 taking placebo) in the valuables study group. RESULTS: Twenty six of the 36 @entity1092 -chrono-treated @entity1 responded by 6 weeks, versus six of the 38 placebo-treated @entity1 (p<0.001). The most common and problematic side effect in the @entity1092 -chrono group was @entity1296 and @entity390 . CONCLUSIONS: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of a @entity1092 -chrono in the management of @entity148 . They need to be replicated in a larger study group.

@entity1092 ( XXXX -chrono) in the acute treatment of outpatients with @entity148 without psychiatric comorbidity: randomized, double-blind placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient', 'men'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproate', 'depakine'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety disorders', 'GAD', 'Anxiety disorders', 'generalized anxiety disorder'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']
@entity1092 :: (MESH:D014635,Chemical) :: ['depakine']
